Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Cosmetic – antiperspirant – dentifrice
Patent
1996-09-11
1997-09-16
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Cosmetic, antiperspirant, dentifrice
424464, 424687, 424690, 424692, A61K 3300
Patent
active
056677944
ABSTRACT:
A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg.
A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg, and an antacid. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg.
REFERENCES:
patent: 4283408 (1981-08-01), Hirata et al.
patent: 5229137 (1993-07-01), Wolfe
Pepcid AC Acid Control Product Monograph (published 1994).
"The Liberator . . . " (The Pharmaceutical Journal, May 7, 1994).
Chremos, A. N., "Clinical Pharmacology of Famotidine: A Summary", J. Clin. Gastroenterol, vol.9(Suppl. 2), pp. 7-12 (1987).
Thompson, et al., "Heartburn and globus in apparently healthy people", CMA Journal, vol. 126, pp. 46-48 (1982).
Laskin, et al., "Pharmacodynamics and Dose-Response Relationship of Famotidine: A Double-Blind Randomized Placebo-Controlled Trial", J. Clin. Pharmacol, vol. 33, pp. 636-639 (1993).
McCallum et al., "MK-208, A Novel Histamine H2-Receptor Inhibitor with Prolonged Antisecretory Effect", Digestive Diseases and Sciences, vol. 30, pp. 1139-1144 (1985).
Gitlin et al., "A Multiclinic Double-Blind Dose Ranging Study Evaluating the Efficacy and Safety of Famotidine in the Healing of Active Duodenal Ulcer as compared to Placebo", Amer. Journal of Gastroenterology, vol. 80, p. 840 (1985).
Miyoshi et al., "Clinical Evaluation of Famotidine on Acute Gastric Mucosal Lesions Associated with Acute Gastritis and Chronic Gastritis-Dose Finding Study by the Double Blind Comparative Method-", Naika Hokan, vol. 34, pp. 442-457 (1987).
Douds, Andrew C. and J. Douglas Maxwell, "Over the counter H2 receptor antagonists", BMJ, (Letters) vol. 309, p. 1156 (1994).
Cooper, J.R.B., "Increase the risks to offshore workers", BMJ, (Letters), vol. 309, pp. 1156-1157 (1994).
Simon et al., "Self-Directed Treatment of Intermittent Heartburn: A Randomized, Multicenter, Double-Blind(DB), Placebo(P)-Controlled Evaluation of Famotidine(FAM) 5, 10 & 20MG and Antacid(AA)", Esophageal, Gastric, and Duodenal Disorders, p. A181 (1994).
MSD Merck Sharp & Dohme, "PEPCID Insert".
F-D-C Reports--"The Tan Sheet" pp. 9-11, Apr. 18, 1994.
Berlin Roger
Simon Thomas
Howard Sharon
Merck & Co. , Inc.
Page Thurman K.
Parr Richard S.
Winokur Mel
LandOfFree
Heartburn treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heartburn treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heartburn treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-216290